Endocrine therapy: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Endocrine therapy

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• Application of Radiomics in Breast Cancer
  NCT04483804 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
  NCT05983107 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
  NCT05904964 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 3 locations
• ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
  NCT06195709 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
  NCT06341894 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer
  NCT04921137 · Phase: Phase 4 · Ages: 70 Years and older · Sex: All (male and female) · 8 locations
• Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
  NCT05693766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
  NCT06044623 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 12 locations
• Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study
  NCT07613151 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
  NCT05306041 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
  NCT05919108 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
  NCT06914440 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
  NCT04923542 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
  NCT04476485 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 12 locations

Common questions

How many recruiting trials involve Endocrine therapy?

16 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.